Revvity, Inc. (RVTY) — Analysis Summary
Revvity, Inc. (RVTY) has a market cap of $14.47B with year-over-year revenue growth of +3.7%. Net margin stands at 8.4%. The stock trades at a P/E ratio of 60.9.
Key Takeaways
- Revenue changed +3.7% year-over-year
- Net margin of 8.4%
- P/E ratio of 60.9
Compared to other companies in the LABORATORY ANALYTICAL INSTRUMENTS sector, RVTY posted revenue growth of +3.7% and trades at a P/E of 60.9.
Revvity, Inc. (RVTY)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Debt/EBITDA at 4.2x — elevated leverage
Operating margin (12.3%) exceeds gross margin (0.0%) — check for other operating income or data classification issues
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Employees
11,000
Headquarters
WALTHAM, MA
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$0.28
Dividend Yield
0.22%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.